JP6449845B2 - 疼痛の処置のためのナトリウムチャネルモジュレーター - Google Patents
疼痛の処置のためのナトリウムチャネルモジュレーター Download PDFInfo
- Publication number
- JP6449845B2 JP6449845B2 JP2016501972A JP2016501972A JP6449845B2 JP 6449845 B2 JP6449845 B2 JP 6449845B2 JP 2016501972 A JP2016501972 A JP 2016501972A JP 2016501972 A JP2016501972 A JP 2016501972A JP 6449845 B2 JP6449845 B2 JP 6449845B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- pain
- sulfamoyl
- compound
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UHZFGTXFKBGFMX-UHFFFAOYSA-N CC(OCC(O1)=C(C)OC1=O)=O Chemical compound CC(OCC(O1)=C(C)OC1=O)=O UHZFGTXFKBGFMX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787618P | 2013-03-15 | 2013-03-15 | |
| US61/787,618 | 2013-03-15 | ||
| PCT/US2014/025809 WO2014151472A1 (en) | 2013-03-15 | 2014-03-13 | Sodium channel modulators for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512844A JP2016512844A (ja) | 2016-05-09 |
| JP2016512844A5 JP2016512844A5 (OSRAM) | 2017-09-07 |
| JP6449845B2 true JP6449845B2 (ja) | 2019-01-09 |
Family
ID=51580969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501972A Active JP6449845B2 (ja) | 2013-03-15 | 2014-03-13 | 疼痛の処置のためのナトリウムチャネルモジュレーター |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10179781B2 (OSRAM) |
| EP (1) | EP2968234B1 (OSRAM) |
| JP (1) | JP6449845B2 (OSRAM) |
| KR (1) | KR20150131254A (OSRAM) |
| CN (1) | CN105188694B (OSRAM) |
| AU (1) | AU2014234105B2 (OSRAM) |
| BR (1) | BR112015022096A8 (OSRAM) |
| CA (1) | CA2900604A1 (OSRAM) |
| ES (1) | ES2687481T3 (OSRAM) |
| HK (1) | HK1219060A1 (OSRAM) |
| IL (1) | IL242564A0 (OSRAM) |
| MX (1) | MX363680B (OSRAM) |
| MY (1) | MY188139A (OSRAM) |
| PH (1) | PH12015501740A1 (OSRAM) |
| RU (1) | RU2669367C2 (OSRAM) |
| WO (1) | WO2014151472A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2853439A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| CA2855019A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| WO2013177224A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
| EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| ES2687481T3 (es) | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
| KR20160054570A (ko) * | 2013-09-10 | 2016-05-16 | 크로모셀 코포레이션 | 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP2017527573A (ja) * | 2014-09-09 | 2017-09-21 | クロモセル コーポレーション | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 |
| CN104710379B (zh) * | 2015-03-09 | 2017-01-18 | 华南理工大学 | 一种bms‑191011的合成方法 |
| CR20170591A (es) | 2015-05-22 | 2018-05-07 | Genentech Inc | Benzamidas sustituidas y métodos para utilizarlas |
| EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| PE20181003A1 (es) | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| US10441586B2 (en) | 2015-10-07 | 2019-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 SUMOylation inhibitors and uses thereof |
| WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| EA201891313A1 (ru) | 2015-12-18 | 2018-11-30 | Мерк Шарп И Доум Корп. | Замещенные гидроксиалкиламинами и гидроксициклоалкиламинами соединения диаминарилсульфонамидов с избирательной активностью в потенциалзависимых натриевых каналах |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA46546A (fr) | 2016-10-17 | 2021-05-05 | Genentech Inc | Composés thérapeutiques et leurs procédés d'utilisation |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| WO2019165290A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| HRP20241195T1 (hr) | 2018-09-10 | 2024-11-22 | Kaken Pharmaceutical Co., Ltd. | Novi heteroaromatski amidni derivat i lijek koji ga sadrži |
| EP3920930A4 (en) * | 2019-02-04 | 2023-03-08 | Simon Fraser University | METHODS AND COMPOUNDS FOR INHIBITION OF INACTIVATION OF VOLTAGE-SENSITIVE SODIUM CHANNELS |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905971A (en) * | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| NZ540574A (en) * | 2001-03-14 | 2006-11-30 | Gruenenthal Chemie | Substituted thiazolopyrimidines used as analgesics |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
| RU2006107211A (ru) * | 2003-08-08 | 2007-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| CA2564355C (en) | 2004-05-07 | 2012-07-03 | Amgen Inc. | Protein kinase modulators and method of use |
| JP4056081B1 (ja) * | 2004-07-23 | 2008-03-05 | ファイザー・インク | ピリジン誘導体 |
| KR20070068432A (ko) | 2004-10-29 | 2007-06-29 | 아스트라제네카 아베 | 염증 질환의 치료를 위한 글루코코르티코이드 수용체조절제로서의 신규 술폰아미드 유도체 |
| AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| CN101336229B (zh) | 2005-12-23 | 2012-06-13 | 西兰岛药物有限公司 | 改性的拟赖氨酸化合物 |
| EP2175728B1 (en) | 2007-07-13 | 2014-09-10 | Icagen, Inc. | Sodium channel inhibitors |
| CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| NZ593473A (en) * | 2009-01-12 | 2013-02-22 | Pfizer Ltd | Sulfonamide derivatives |
| CN102448937A (zh) | 2009-05-29 | 2012-05-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| EP2560636A4 (en) | 2010-04-23 | 2013-11-27 | Kineta Inc | ANTIVIRAL CONNECTIONS |
| EP2590951B1 (en) * | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| CA2803118C (en) * | 2010-07-09 | 2015-11-03 | Pfizer Limited | Sulfonamide derivatives as nav 1.7 inhibitors |
| JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体 |
| CN103492575A (zh) | 2011-01-18 | 2014-01-01 | 安姆根有限公司 | NaV1.7敲除小鼠及其用途 |
| CA2844799A1 (en) | 2011-08-17 | 2013-02-21 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| CA2855019A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| US9757379B2 (en) | 2012-11-14 | 2017-09-12 | The Board Of Regents Of The University Of Texas System | Inhibition of HIF-2α heterodimerization with HIF1β (ARNT) |
| ES2687481T3 (es) | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
| SI3043784T1 (sl) | 2013-09-09 | 2019-08-30 | Peloton Therapeutics, Inc. | Aril etri in njihova uporaba |
| KR20160054570A (ko) | 2013-09-10 | 2016-05-16 | 크로모셀 코포레이션 | 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 |
-
2014
- 2014-03-13 ES ES14767550.8T patent/ES2687481T3/es active Active
- 2014-03-13 CA CA2900604A patent/CA2900604A1/en active Pending
- 2014-03-13 EP EP14767550.8A patent/EP2968234B1/en not_active Not-in-force
- 2014-03-13 CN CN201480014410.XA patent/CN105188694B/zh not_active Expired - Fee Related
- 2014-03-13 MY MYPI2015702635A patent/MY188139A/en unknown
- 2014-03-13 WO PCT/US2014/025809 patent/WO2014151472A1/en not_active Ceased
- 2014-03-13 HK HK16107214.7A patent/HK1219060A1/zh unknown
- 2014-03-13 RU RU2015133310A patent/RU2669367C2/ru not_active IP Right Cessation
- 2014-03-13 AU AU2014234105A patent/AU2014234105B2/en not_active Ceased
- 2014-03-13 JP JP2016501972A patent/JP6449845B2/ja active Active
- 2014-03-13 US US14/776,016 patent/US10179781B2/en active Active
- 2014-03-13 MX MX2015011907A patent/MX363680B/es unknown
- 2014-03-13 KR KR1020157029193A patent/KR20150131254A/ko not_active Abandoned
- 2014-03-13 BR BR112015022096A patent/BR112015022096A8/pt not_active IP Right Cessation
-
2015
- 2015-08-07 PH PH12015501740A patent/PH12015501740A1/en unknown
- 2015-11-12 IL IL242564A patent/IL242564A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014234105A1 (en) | 2015-09-03 |
| RU2015133310A3 (OSRAM) | 2018-02-28 |
| MY188139A (en) | 2021-11-23 |
| PH12015501740A1 (en) | 2015-10-19 |
| IL242564A0 (en) | 2016-02-29 |
| CA2900604A1 (en) | 2014-09-25 |
| BR112015022096A2 (pt) | 2017-07-18 |
| EP2968234A1 (en) | 2016-01-20 |
| CN105188694A (zh) | 2015-12-23 |
| JP2016512844A (ja) | 2016-05-09 |
| MX363680B (es) | 2019-03-29 |
| US20160046617A1 (en) | 2016-02-18 |
| EP2968234A4 (en) | 2016-10-12 |
| RU2669367C2 (ru) | 2018-10-11 |
| US10179781B2 (en) | 2019-01-15 |
| AU2014234105B2 (en) | 2019-01-03 |
| WO2014151472A1 (en) | 2014-09-25 |
| RU2015133310A (ru) | 2017-04-20 |
| ES2687481T3 (es) | 2018-10-25 |
| CN105188694B (zh) | 2018-07-31 |
| MX2015011907A (es) | 2016-05-16 |
| HK1219060A1 (zh) | 2017-03-24 |
| EP2968234B1 (en) | 2018-06-27 |
| KR20150131254A (ko) | 2015-11-24 |
| BR112015022096A8 (pt) | 2019-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6449845B2 (ja) | 疼痛の処置のためのナトリウムチャネルモジュレーター | |
| JP6445565B2 (ja) | とう痛及び糖尿病の治療用ナトリウムチャネル調節物質 | |
| JP6351182B2 (ja) | ガンの治療方法 | |
| ES2786298T3 (es) | Inhibidores de benzimidazol del canal de sodio | |
| US8247401B2 (en) | P2X3 receptor antagonists for treatment of pain | |
| JP5552430B2 (ja) | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト | |
| JP2012521429A (ja) | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト | |
| JP2015536308A5 (OSRAM) | ||
| JP2014514259A (ja) | 疼痛および他の障害の処置のための化合物および方法 | |
| JP2017527573A (ja) | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 | |
| US20110230452A1 (en) | Compounds and methods for the treatment of pain and other diseases | |
| US20220280644A1 (en) | "TRPswitch" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND | |
| HK1224572A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| JP2015166385A (ja) | 疼痛および他の障害の処置のための化合物および方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170707 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6449845 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |